Not provided
Not provided
Not provided
Not provided
Not provided
PI failed to file continuation report.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effects of 35 EECP sessions on cardiopulmonary training performance in healthy volunteers. Data from this study will be used to generate sample size and power calculations for feasibility of future EECP studies. The results of this study could provide evidence that can help active duty and Department of Defense beneficiaries optimize physical conditioning, endurance and overall health.
The purpose of this study is to assess the effects of 35 EECP sessions on cardiopulmonary training performance in healthy volunteers. Prior published and anecdotal evidence suggests that EECP should improve athletic performance. Data from this study will be used to generate sample size and power calculations for feasibility of future EECP studies. The results of this study could provide evidence that can help active duty and Department of Defense beneficiaries optimize physical conditioning, endurance and overall health. It could help active duty members maximize their physical training potential enabling them to better prepare for missions down range. Additionally, physiologic cardiopulmonary improvements may have the potential to decrease the conditioning time required for injured, post-operative and post-partum active duty members to return to duty.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| EECP Treatment | Other | 35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enhanced External Counterpulsation (EECP) | Device | EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers. |
| Measure | Description | Time Frame |
|---|---|---|
| VO2 MAX | The primary endpoint will be the change from baseline in VO2 MAX over the 7-week EECP treatment period. | 7 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| 1.5 run run | The secondary endpoint will be the change in 1.5 mile run time pre/post a 7-week course of EECP therapy. | 7 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Exploratory endpoints peripheral blood pressures | Assessment of peripheral blood pressures levels. | 7 weeks |
| Exploratory endpoints Central Blood Pressure | Assessment of Central Blood Pressure levels |
Inclusion Criteria:
Healthy active-duty military personnel or DoD beneficiaries
18 years or older [no age cutoff is needed, subjects will be medically cleared via PI's discretion or physician consultation letter]
Scoring below 55 out of 60 points on a 1.5 mile run portion of test using current AFI fitness standards [adjusted for age and gender]
Maintaining a steady work-out routine and agreeing to adhere to it for the duration of the study. The workouts cannot vary by greater than 50% week to week (e.g. a subject that works out 3 hours on week 1, can only work out between 1.5 to 4.5 hours on week 2).
Dermatological conditions not impacted by the EECP procedure will be allowed to enroll (e.g. eczema).
Exclusion Criteria:
Pregnancy or anticipated pregnancy
Exemption from PT (run portion of physical fitness test)
VO2MAX greater than 55 mL/kg/min [determined from baseline CPX]
Scheduled permanent change in station within 3 months
Any significant co-morbid health conditions medically classifying the subject as not healthy [at PI's discretion], including but not limited to the following.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sokunthea Peou, Pharmacist | David Grant Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| David Grant AF Medical Center | Travis Air Force Base | California | 94535 | United States |
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D008171 | Lung Diseases |
| ID | Term |
|---|---|
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 7 weeks |
| Exploratory endpoints Augmentation index | Assessment of Augmentation index | 7 weeks |
| Exploratory endpoints VEGF | Assessment of VEGF | 7 weeks |